Canadian Halal Investor.

NYSE Shariah screener · October 2026

Is AbbVie Inc. (ABBV) Halal?

PASS

AbbVie Inc. · NYSE: ABBV · Healthcare

The short answer

Yes — AbbVie Inc. (ABBV) passes this Shariah stock screen. The global biopharmaceutical company (immunology: Skyrizi, Rinvoq, Humira; neuroscience; oncology; aesthetics via Botox Cosmetic and Juvederm) has no disclosed prohibited business lines. Its total debt of $67,496M is about 14.34% of its ~$470.6B market cap ($259.93, October 1, 2026), below the ~33% ceiling. Interest income of $266M is about 0.43% of FY2025 revenue ($61,160M), below the 5% non-compliant income ceiling. Zoya covers ABBV under AAOIFI guidelines (its FAQ flags it Shariah-compliant, though the page's boilerplate template text is conflicting); no Musaffa or ShariaPortfolio coverage was found — honestly reported as absent, not invented.

Gate 1 — Business activity: PASS

AbbVie Inc. (NYSE: ABBV) is a global, diversified research-based biopharmaceutical company, incorporated in Delaware on April 10, 2012 and independent since its January 2013 spin-off from Abbott Laboratories. Per its FY2025 Form 10-K it operates as a single global business segment with leadership positions across immunology (Skyrizi $17.6B, Rinvoq $8.3B, Humira $4.5B in FY2025), neuroscience (Vraylar, Botox Therapeutic, Ubrelvy, Qulipta), oncology (Imbruvica, Venclexta, Elahere) and aesthetics (Botox Cosmetic, Juvederm — via the 2020 Allergan acquisition). No prohibited lines are present — no alcohol, gambling, pork, conventional banking/insurance, tobacco, cannabis, weapons or adult entertainment; no cannabis-related product lines were found in the 10-K business description. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per AbbVie's Form 10-K for fiscal 2025 (year ended December 31, 2025), total debt was $67,496M — short-term borrowings $2,499M, current portion of long-term debt and finance lease obligations $6,056M, and long-term debt and finance lease obligations $58,941M on the consolidated balance sheet (MarketBeat independently reports $67.50B). Against a market cap of about $470.6B (Finnhub; $259.93 on October 1, 2026), debt ÷ market cap is about 14.34%, below the ~33% ceiling. Cash and equivalents ($5,229M) plus short-term investments ($28M) and long-term investments ($268M) total $5,525M, about 1.17% of market cap. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

AbbVie's FY2025 10-K (Note 3) reports interest income of $266M against net revenues of $61,160M — about 0.43% of revenue, below the 5% non-compliant income ceiling (interest expense was $2,893M). Zoya's page independently cites the same $266M interest-income figure from the FY2025 annual report. Gate 3 passes. Facts only.

Key figures used

Frequently asked questions

What does AbbVie do?

AbbVie Inc. (NYSE: ABBV) is a global, diversified research-based biopharmaceutical company, incorporated in Delaware in 2012 and independent since its January 2013 spin-off from Abbott Laboratories. Per its FY2025 10-K it operates as a single global business segment with leadership positions across immunology (Skyrizi $17.6B, Rinvoq $8.3B, Humira $4.5B in FY2025), neuroscience (Vraylar, Botox Therapeutic, Ubrelvy, Qulipta), oncology (Imbruvica, Venclexta, Elahere) and aesthetics (Botox Cosmetic, Juvederm — via the 2020 Allergan acquisition).

Why does AbbVie pass this Shariah stock screen?

AbbVie passes all three gates of this screen. Its business is pure research-based biopharma with no disclosed prohibited lines (no alcohol, gambling, pork, conventional banking/insurance, tobacco, cannabis, weapons or adult entertainment; its aesthetics medicines are elective medical products, not a prohibited industry category). Total debt of $67,496M is about 14.34% of its ~$470.6B market cap, below the ~33% ceiling. Interest income of $266M is about 0.43% of FY2025 revenue ($61,160M), below the 5% non-compliant income ceiling. Zoya covers ABBV under AAOIFI guidelines; no Musaffa or ShariaPortfolio coverage was found. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

What is AbbVie's interest-bearing debt ratio?

Per AbbVie's Form 10-K for fiscal 2025 (fiscal year ended December 31, 2025), total debt was $67,496M — short-term borrowings $2,499M, current portion of long-term debt and finance lease obligations $6,056M, and long-term debt and finance lease obligations $58,941M on the consolidated balance sheet (MarketBeat cross-checks $67.50B). Against a market cap of about $470.6B (Finnhub; $259.93, October 1, 2026), debt ÷ market cap is about 14.34% — below the ~33% ceiling. Cash and equivalents ($5,229M) plus short-term investments ($28M) and long-term investments ($268M) total $5,525M, about 1.17% of market cap.

What is AbbVie's non-compliant income ratio?

AbbVie's FY2025 10-K (Note 3) reports interest income of $266M against net revenues of $61,160M — about 0.43% of revenue, below the 5% non-compliant income ceiling (interest expense was $2,893M, i.e., $2,627M net interest expense). Zoya's page independently cites the same $266M interest-income figure from the FY2025 annual report.

Do Zoya, Musaffa, or ShariaPortfolio cover AbbVie?

Zoya covers ABBV under AAOIFI guidelines (zoya.finance/stocks/abbv): its substantive FAQ states ABBV is flagged as Shariah-compliant and reports the same $266M / $61.16B (0.43%) figures, though the page's boilerplate template text contains conflicting variants, so the rating is reported as covered with ambiguous page text rather than a clean quote. No Musaffa coverage of ABBV was found (site:musaffa.com search returned nothing), and no ShariaPortfolio rating for ABBV was found — both honestly reported as absent, not invented. This page applies the screen directly from AbbVie's own filings.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).